Baricitinib for the treatment of cutaneous dermatomyositis: A prospective, open-label study

Abstract

To the Editor: The unmet need for skin disease control poses a clinical challenge in dermatomyositis (DM). Conventional therapies, such as glucocorticoids and nonspecific immunosuppressants, are limited by the potential side effects and delayed onset of action.1 Mechanism-based treatments targeting the Janus kinase (JAK)–signal transducer and activator of transcription signaling pathway have exhibited efficacy in DM patients.2,3 However, there is a dearth of research investigating the efficacy and safety of JAK inhibitors in treating skin-predominant DM.